{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:45:36Z","timestamp":1778939136310,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88882.434900\/2019\u201001"],"award-info":[{"award-number":["88882.434900\/2019\u201001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.513974\/2020-00"],"award-info":[{"award-number":["88887.513974\/2020-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["141200\/2018-9"],"award-info":[{"award-number":["141200\/2018-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2019\/05718-3"],"award-info":[{"award-number":["2019\/05718-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s12032-021-01551-5","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T08:02:50Z","timestamp":1627113770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Metabolic shift of chronic myeloid leukemia patients under imatinib\u2013pioglitazone regimen and discontinuation"],"prefix":"10.1007","volume":"38","author":[{"given":"Valqu\u00edria Mariane Oliveira","family":"P\u00f3voa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeany","family":"Delafiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via Lu\u00edsa","family":"Dias-Audibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Noin","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Beatriz Pascoal","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erich Vin\u00edcius","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia Borgia Barbosa","family":"Pagnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7219-2644","authenticated-orcid":false,"given":"Rodrigo Ramos","family":"Catharino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"key":"1551_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17474086.2018.1442213","volume":"11","author":"RP Gale","year":"2018","unstructured":"Gale RP, Hochhaus A. Therapy-free remission in chronic myeloid leukemia: possible mechanism. Expert Rev Hematol. 2018;11:269\u201372.","journal-title":"Expert Rev Hematol"},{"key":"1551_CR2","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1021\/acs.jproteome.6b00356","volume":"15","author":"R Karl\u00edkov\u00e1","year":"2016","unstructured":"Karl\u00edkov\u00e1 R, \u0160irok\u00e1 J, Friedeck\u00fd D, Faber E, Hrd\u00e1 M, Mi\u010dov\u00e1 K, et al. Metabolite profiling of the plasma and leukocytes of chronic myeloid leukemia patients. J Proteome Res. 2016;15:3158\u201366.","journal-title":"J Proteome Res"},{"key":"1551_CR3","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MWN Deininger","year":"2000","unstructured":"Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343\u201356.","journal-title":"Blood"},{"key":"1551_CR4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.molcel.2012.08.033","volume":"48","author":"DR Donohoe","year":"2012","unstructured":"Donohoe DR, Collins LB, Wali A, Bigler R, Sun W, Bultman SJ. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 2012;48:612\u201326.","journal-title":"Mol Cell"},{"key":"1551_CR5","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1158\/1078-0432.CCR-04-0039","volume":"10","author":"S Gottschalk","year":"2004","unstructured":"Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res. 2004;10:6661\u20138.","journal-title":"Clin Cancer Res"},{"key":"1551_CR6","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851\u20137.","journal-title":"J Clin Oncol"},{"key":"1551_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"1551_CR8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/10428194.2017.1379074","volume":"59","author":"G Saglio","year":"2018","unstructured":"Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma. 2018;59:1523\u201338.","journal-title":"Leuk Lymphoma"},{"key":"1551_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966\u201384.","journal-title":"Leukemia"},{"key":"1551_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/sj.bjc.6604946","volume":"100","author":"J Klawitter","year":"2009","unstructured":"Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, et al. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer. 2009;100:923\u201331.","journal-title":"Br J Cancer"},{"key":"1551_CR11","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3). J Biol Chem. 1995;270:12953\u20136.","journal-title":"J Biol Chem"},{"key":"1551_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists. Nature. 2015;525:380\u20133.","journal-title":"Nature"},{"key":"1551_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.febslet.2007.11.016","volume":"582","author":"J Sonoda","year":"2008","unstructured":"Sonoda J, Pei L, Evans RM. Nuclear receptors: decoding metabolic disease. FEBS Lett. 2008;582:2\u20139.","journal-title":"FEBS Lett"},{"key":"1551_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003495-200666010-00005","volume":"66","author":"J Waugh","year":"2006","unstructured":"Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. Pioglitazone. Drugs. 2006;66:85\u2013109.","journal-title":"Drugs"},{"key":"1551_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2005.08.011","volume":"58","author":"T Wang","year":"2006","unstructured":"Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor \u03b3 in malignant diseases. Crit Rev Oncol Hematol. 2006;58:1\u201314.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1551_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"PJ Hsiao","year":"2017","unstructured":"Hsiao PJ, Chiou HYC, Jiang HJ, Lee MY, Hsieh TJ, Kuo KK. Pioglitazone enhances cytosolic lipolysis, \u03b2-oxidation and autophagy to ameliorate hepatic steatosis. Sci Rep. 2017;7:1\u201311.","journal-title":"Sci Rep"},{"key":"1551_CR17","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMra041001","volume":"351","author":"H Yki-J\u00e4rvinen","year":"2004","unstructured":"Yki-J\u00e4rvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106\u201318. https:\/\/doi.org\/10.1056\/NEJMra041001.","journal-title":"N Engl J Med"},{"key":"1551_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1182\/blood.V120.21.696.696","volume":"120","author":"P Rousselot","year":"2012","unstructured":"Rousselot P, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, et al. Targeting STAT5 expression resulted in molecular response improvement in patients with chronic phase CML treated with imatinib. Blood. 2012;120:696.","journal-title":"Blood"},{"key":"1551_CR19","doi-asserted-by":"publisher","first-page":"E321","DOI":"10.1002\/ajh.25986","volume":"95","author":"KBB Pagnano","year":"2020","unstructured":"Pagnano KBB, Lopes ABP, Miranda EC, Delamain MT, Duarte GO, Rodrigues BRV, et al. Efficacy and safety of pioglitazone in a phase 1\/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response. Am J Hematol. 2020;95:E321\u20133.","journal-title":"Am J Hematol"},{"key":"1551_CR20","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2019-128265","volume":"134","author":"ABP Lopes","year":"2019","unstructured":"Lopes ABP, Miranda EC, P\u00f3voa VMO, Verg\u00edlio BR, Furlin GCP, Delamain MT, et al. Pioglitazone did not affect PPAR-\u0393, STAT5, HIF2\u03b1 and CITED2 gene expression in chronic myeloid leukemia patients with deep molecular response. Blood. 2019;134:1637.","journal-title":"Blood"},{"key":"1551_CR21","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.30490","volume":"123","author":"P Rousselot","year":"2017","unstructured":"Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, et al. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study. Cancer. 2017;123:1791\u20139.","journal-title":"Cancer"},{"key":"1551_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/cas.13500","volume":"109","author":"B Yang","year":"2018","unstructured":"Yang B, Wang C, Xie Y, Xu L, Wu X, Wu D. Monitoring tyrosine kinase inhibitor therapeutic responses with a panel of metabolic biomarkers in chronic myeloid leukemia patients. Cancer Sci. 2018;109:777\u201384.","journal-title":"Cancer Sci"},{"key":"1551_CR23","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White HE, M\u00fcller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172\u20135.","journal-title":"Leukemia"},{"key":"1551_CR24","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1021\/acs.analchem.0c04497","volume":"93","author":"J Delafiori","year":"2021","unstructured":"Delafiori J, Navarro LC, Siciliano RF, de Melo GC, Busanello ENB, Nicolau JC, et al. Covid-19 automated diagnosis and risk assessment through metabolomics and machine learning. Anal Chem. 2021;93:2471\u20139.","journal-title":"Anal Chem"},{"key":"1551_CR25","doi-asserted-by":"publisher","first-page":"15534","DOI":"10.1038\/s41598-020-72664-6","volume":"10","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Wong L, Goh WWB. How to do quantile normalization correctly for gene expression data analyses. Sci Rep. 2020;10:15534.","journal-title":"Sci Rep"},{"key":"1551_CR26","series-title":"Methods in molecular biology","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/978-1-0716-0239-3_17","volume-title":"Using MetaboAnalyst 4.0 for metabolomics data analysis, interpretation, and integration with other omics data","author":"J Chong","year":"2020","unstructured":"Chong J, Xia J. Using MetaboAnalyst 4.0 for metabolomics data analysis, interpretation, and integration with other omics data. Methods in molecular biology. New York: Springer; 2020. p. 337\u201360."},{"key":"1551_CR27","first-page":"1286","volume":"66","author":"M Hussian","year":"2016","unstructured":"Hussian M, Arain AQ, Chiragh S. Pioglitazone improves serum lipid profile in diet induced hyperlipidaemic non diabetic rats. J Pak Med Assoc. 2016;66:1286\u201390.","journal-title":"J Pak Med Assoc"},{"key":"1551_CR28","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nrm.2017.76","volume":"18","author":"R Zechner","year":"2017","unstructured":"Zechner R, Madeo F, Kratky D. Cytosolic lipolysis and lipophagy: two sides of the same coin. Nat Rev Mol Cell Biol. 2017;18:671.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1551_CR29","doi-asserted-by":"crossref","unstructured":"Lehner R, Quiroga AD. Fatty acid handling in mammalian cells. In: Ridgway N, McLeod R, editors. Biochemistry of lipids, lipoproteins and membranes. 6th edn. Elsevier; 2016. pp. 149\u201384.","DOI":"10.1016\/B978-0-444-63438-2.00005-5"},{"key":"1551_CR30","doi-asserted-by":"publisher","first-page":"C33","DOI":"10.1152\/ajpcell.00243.2006","volume":"292","author":"AJ Chicco","year":"2007","unstructured":"Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am J Phys Cell Physiol. 2007;292:C33\u201344.","journal-title":"Am J Phys Cell Physiol"},{"key":"1551_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.tcb.2015.12.007","volume":"26","author":"Y Wang","year":"2016","unstructured":"Wang Y, Hekimi S. Understanding ubiquinone. Trends Cell Biol. 2016;26:367\u201378.","journal-title":"Trends Cell Biol"},{"key":"1551_CR32","doi-asserted-by":"publisher","first-page":"e21924","DOI":"10.1371\/journal.pone.0021924","volume":"6","author":"J Kluza","year":"2011","unstructured":"Kluza J, Jendoubi M, Ballot C, Dammak A, Jonneaux A, Idziorek T, et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One. 2011;6:e21924.","journal-title":"PLoS One"},{"key":"1551_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108:319\u201327.","journal-title":"Blood"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01551-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01551-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01551-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T06:47:14Z","timestamp":1629787634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01551-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01551-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KBBP declares advisory board:\u00a0Astellas,\u00a0Abbvie, Novartis; lectures: EMS,\u00a0Pintpharma, Jansen,\u00a0and Astellas. The other authors declare no conflict of interests. All authors have read the journal\u2019s policy on disclosure of potential conflicts of interest. The authors have full control of all primary data and agree to provide it to journal review if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of Unicamp (CEP-Unicamp: Comit\u00ea de \u00c9tica em Pesquisa da Unicamp\u2014Campus Campinas), Number CAAE: 54899916.5.0000.5404.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"A written informed consent was obtained from all patients prior to enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the final version of the final manuscript and were responsible for the decision to submit for publication. The manuscript does not present identifiable patient data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"100"}}